Logo

Prestige BioPharma Publishes the Results of Tuznue (biosimilar, trastuzumab) in the JAMA Oncology

Share this

Prestige BioPharma Publishes the Results of Tuznue (biosimilar, trastuzumab) in the JAMA Oncology

Shots:

  • The P-III study evaluates the efficacy and safety of patients who received HD201 (Tuznue) vs Herceptin for 1yr. and completed a median follow-up of 31mos.
  • The study met its 1EPs i.e. tpCR rates (45% vs 48.7%), and showed equivalent efficacy and comparable safety profile. The 2EPs including bpCR, overall response, and response based on mammography, ultrasonography, or clinical tumor evaluations, also supported the efficacy of Tuznue
  • The company is currently evaluating 3yrs. EFS and OS result in an ongoing study. The preliminary results of this final analysis indicate highly comparable 3yrs. EFS and OS rates for HD201 and Herceptin

Ref: Businesswire | Image: Prestige Biopharma

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions